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Abstract
Background
The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation
(AF) is not known. Therefore, it is not possible to determine the number needed to screen
(NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation
[OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each
age stratum, precise cost-effectiveness and sensitivity simulations can be performed based
on the age distribution of the population/region to be screened. Such calculations are
required by national authorities and organisations responsible for health system budgets to
determine the best age cutoffs for screening programs and decide whether programs of
screening should be funded. Therefore, we aimed to determine the exact yield and calcu-
lated stroke-risk profile of screen-detected AF and NNS-Rx in 5-year age strata.
Methods and findings
A systematic review of Medline, Pubmed, and Embase was performed (January 2007 to
February 2018), and AF-SCREEN international collaboration members were contacted to
identify additional studies. Twenty-four eligible studies were identified that performed a sin-
gle time point screen for AF in a general ambulant population, including people�65 years.
Authors from eligible studies were invited to collaborate and share patient-level data. Statis-
tical analysis was performed using random effects logistic regression for AF detection rate,
and Poisson regression modelling for CHA2DS2-VASc scores. Nineteen studies (14 coun-
tries from a mix of low- to middle- and high-income countries) collaborated, with 141,220
participants screened and 1,539 new AF cases. Pooled yield of screening was greater in
males across all age strata. The age/sex-adjusted detection rate for screen-detected AF in
�65-year-olds was 1.44% (95% CI, 1.13%–1.82%) and 0.41% (95% CI, 0.31%–0.53%) for
<65-year-olds. New AF detection rate increased progressively with age from 0.34% (<60
years) to 2.73% (�85 years). Neither the choice of screening methodology or device, the
geographical region, nor the screening setting influenced the detection rate of AF. Mean
CHA2DS2-VASc scores (n = 1,369) increased with age from 1.1 (<60 years) to 3.9 (�85
years); 72% of�65 years had�1 additional stroke risk factor other than age/sex. All new
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Conclusions
People with screen-detected AF are at elevated calculated stroke risk: above age 65, the
majority have a Class-1 OAC recommendation for stroke prevention, and >70% have�1
additional stroke risk factor other than age/sex. Our data, based on the largest number of
screen-detected AF collected to date, show the precise relationship between yield and esti-
mated stroke risk profile with age, and strong dependence for NNS-RX on the age distribu-
tion of the population to be screened: essential information for precise cost-effectiveness
calculations.
Author summary
Why was this study done?
• Atrial fibrillation is a common heart rhythm problem that often has no symptoms, so
people are unaware they have this condition.
• People with atrial fibrillation can have a very high stroke risk if they are not appropri-
ately treated with anticoagulant medications, and this risk increases with age.
• Screening for atrial fibrillation is recommended in many guidelines, although the pre-
cise age distribution and calculated stroke risk of atrial fibrillation detected by screening
is not known.
• Accurate age-specific data are required for cost-effectiveness analysis, to inform the
most appropriate age cutoff for screening based on the age distribution of the popula-
tion to be screened.
What did the researchers do and find?
• Investigators from 19 atrial fibrillation screening studies across the world agreed to col-
laborate and share patient-level data, providing a combined database of 141,220 people
screened and 1,539 screen-detected cases of atrial fibrillation.
• Our study was able to quantify the yield and stroke risk for atrial fibrillation in 5-year
age brackets, showing the exact relationship of how the yield of screening and stroke
risk of screen-detected atrial fibrillation increases with age.
• The yield of screening was not influenced by the screening method used or the recruit-
ment setting, indicating that screening programs can be established based on available
resources.
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• To our knowledge, this is the first study to demonstrate the precise relationship of the
number that need to be screened to identify one new atrial fibrillation case, or one new
atrial fibrillation case in whom anticoagulant treatment is guideline recommended, in
5-year age brackets.
What do these findings mean?
• This study demonstrates the high calculated stroke risk of screen-detected AF and the
high proportion with at least one additional stroke risk factor other than age or sex.
• These data allow for accurate simulations of cost-effectiveness of screening, including
sensitivity analyses, based on the age distribution of the population to be screened.
• Ultimately, these data may be used to assist development of health policy around the
development of atrial fibrillation screening programs, tailored to the specific health sys-
tem and resources available.
Introduction
The role of opportunistic or systematic atrial fibrillation (AF) screening for people aged�65
years remains contested, with variation in recommendations between international AF clinical
guidelines. However, 10% of all ischaemic strokes are in individuals with undiagnosed AF [1],
and early identification of AF and appropriate guideline-based oral anticoagulation (OAC)
treatment can prevent strokes and thus reduce health costs related to AF [2]. Organisations
supporting the recommendation to screen include the European Society of Cardiology (ESC)
[3], the European Heart Rhythm Association [4], the Royal College of Physicians of Edinburgh
[5], AF-SCREEN International Collaboration [6], and, recently, the Heart Foundation of Aus-
tralia and the Cardiac Society of Australia and New Zealand [7].
The evidence to support screening has mainly been extrapolated from studies of people
with clinically or incidentally diagnosed AF and from prevalence studies that show both AF
prevalence and stroke risk increase substantially from age 65. No large outcome trial of screen-
detected AF using hard events, including stroke and death, has been reported to date. Few
studies have reported the baseline estimated stroke risk of screen-detected AF patients. In the
screening for atrial fibrillation in the elderly (SAFE) trial, the calculated stroke risk was the
same in screen-detected and symptomatically identified AF patients [8], but it was not possible
to accurately determine the stroke risk in discrete age strata or the number needed to screen
(NNS) to identify one treatable new AF case (NNS-Rx) in each age stratum. This information
is important for precise cost-effectiveness and sensitivity simulations based on the age distribu-
tion of the population to be screened. Such calculations are required by payers to determine
the best age cutoffs for screening programs and decide whether programs of screening should
be funded.
We therefore performed a systematic review and meta-analysis to investigate the yield of
new AF identified in contemporary AF screening studies (single time point) and to explore the
stroke risk profile and OAC eligibility of those identified, in order to determine the precise age
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Methods
This systematic review and patient-level meta-analysis was performed in accordance with the
preferred reporting items for systematic reviews and meta-analysis (S1 PRISMA checklist) and
the meta-analyses of observational studies in epidemiology guidelines [9,10]. All collaborating
studies had ethical approval for their study, the details of which are reported in the individual
study manuscripts [11–29]. Ethical approval was not required for this collaborative secondary
analysis of data.
Search strategy and selection criteria
Relevant studies were identified by two independent reviewers (NL and BF) through electronic
database searching of MEDLINE, Pubmed, Embase, and Google. The keyword search terms
used were as follows: atrial fibrillation AND [screening OR incidence OR prevalence OR
detection OR identification] up to February 2018. To ensure a relevant contemporary sample
was obtained, limits were applied to years 2007 onwards, and human research. Studies pub-
lished in any language were permitted. Additional studies were identified through directly
contacting members of the AF-SCREEN International Collaboration [6]. Study authors from
all eligible studies were contacted via email, with an explanation of the proposed study and an
invitation to collaborate.
The inclusion criteria for screening studies were as follows: (i) evaluated a general ambulant
population; (ii) included people�65 years within their screened population; (iii) used a valid
method to identify AF, as accepted by the ESC 2016 AF guidelines (i.e., pulse palpation,
12-lead electrocardiogram [ECG], or ECG rhythm strip, with a validated device) [3]; (iv)
assessed the rate of newly identified AF using a single time point screen; (v) distinguished
between newly identified AF and previously diagnosed AF; (vi) screened a sample size of at
least 1,000 people; (vii) collected participant age and gender for all new AF; and (viii) collected
participant age for all participants screened. Studies were excluded if they performed repeated,
intermittent, or continuous recordings over a period to identify unknown AF or if screening
was targeted at a specific subgroup (e.g., limited age range, hypertension, diabetes, poststroke).
Assessment of Quality of Reporting was not performed, as some participating studies had
not published their results. However, to ensure only studies of appropriate quality were
included, our study inclusion criteria were intentionally developed based on the modified
Newcastle-Ottawa scale criteria, specifically (i) the source population is representative, (ii) past
history of AF is ascertained, (iii) a validated measurement tool is used, (iv) sample size is ade-
quate, (v) methodology is appropriate for outcomes, and (vi) variables are clearly defined.
Study outcomes
The primary study outcome was the detection rate for cases of new AF identified through
screening of people aged�65 years with one screen at a single time point (reported as [number
of positive cases/100 persons screened] and 95% CI). Secondary outcomes of interest were (i)
detection rate for cases of new AF identified through screening with one screen at a single time
point, stratified according to each age group (<60, 60–64, 65–69, 70–74, 75–79, 80–84, and
�85 years) (reported as [number of positive cases/100 persons screened] and 95% CI); (ii)
CHA2DS2-VASc stroke risk score, stratified according to age group (reported as means and
95% CI); (iii) eligibility for OAC according to ESC 2016 guidelines, stratified according to age
group (reported as number and percentage); (iv) proportion of new AF cases with stroke risk
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factors other than age and sex (i.e., chronic heart failure, hypertension, diabetes, prior stroke
or transient ischaemic attack, or vascular disease), stratified according to age group (reported
as number and percentage); (v) NNS to identify 1 new AF case for age�65 years, stratified
according to age group; and (vi) NNS-Rx (i.e., new AF with a Class-1 recommendation to pre-
scribe OAC) for age�65 years, stratified according to age group.
Statistical analysis
Data from each study were exported into Microsoft Excel (version 1802) and checked for
errors. Data fields collected from each study are summarised in S1 Text. Descriptive analyses
were carried out to describe characteristics of participating studies, total numbers screened,
and total numbers of AF identified through screening, stratified according to age group and
sex.
Detection rate of new AF. The number of new AF cases among those screened was
assumed to follow a binomial distribution, as only a binary outcome was possible from screen-
ing each participant (AF positive or AF negative). In accordance with our statistical analysis
plan, the detection rate of new AF cases was estimated by random effects logistic regression.
As binary data are unlikely to have a ‘normal distribution’, random effects logistic regression is
preferred over conventional meta-analysis approaches that assume study-level effect sizes are
normally distributed [30]. The consequence of choosing this approach is that the standard
meta-analytic methods for detecting heterogeneity and publication bias cannot be applied.
Heterogeneity was therefore assessed using the study-level random effect and standard error.
Individual-level data were available for the screening outcome (AF positive or AF negative),
sex, and age group. Study-level information was available for country, geographical region,
urban/rural population, screening method/device, screening setting/design, era screened, and
screening age eligibility. Due to the combination of both individual and study-level data, the
individual-level data were modelled first, and then the study-level variables were added. Study
was included as a random effect in all models.
For the individual-level data, three models were considered: the intercept only (overall
mean), then the addition of age groups, and then gender. The appropriateness of including
each variable was based on comparison of the Akaike information criterion for each model.
The study-level covariates were then added to the model one at a time, and the Akaike infor-
mation criterion was used to determine if they should be included or not, based on compari-
son to the Akaike information criterion of the final individual-level model.
Individual logistic regression models were used for study-level estimates, and summary
estimates were computed from a random effects logistic regression model using SAS GLIM-
MIX (v9.4) while adjusted for covariates. Age group estimates were computed using least
square means from the final random effects logistic regression model. The results of the analy-
sis from SAS GLIMMIX were imported into R, and the metafor package (R 3.4.3 ‘Kite-Eating
Tree’) was used to create a forest plot. The results were reported for the age group�65 years
and also stratified according to each age group (<60, 60–64, 65–69, 70–74, 75–79, 80–84,�85
years).
Stroke risk profile of new AF cases. Stroke risk of new AF cases was determined using
the CHA2DS2-VASc score (range 0–9 points), which is the sum of risk factors: congestive
heart failure/left ventricular dysfunction (1 point); high blood pressure (1 point); age>75
years (2 points); diabetes (1 point); stroke/transient ischaemic attack/thromboembolism (2
points); vascular disease (coronary artery disease, myocardial infarction, peripheral artery dis-
ease, aortic plaque) (1 point); age 65–74 years (1 point); and sex category female (1 point). The
CHA2DS2-VASc score was chosen to measure stroke risk as it is recommended by most
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international guidelines [3,7,31], and it has demonstrated accuracy identifying AF patients
who are at low risk of stroke and therefore do not require OAC [32,33].
Random effects Poisson regression modelling was performed for the CHA2DS2-VASc
score. As the maximum data value of the CHA2DS2-VASc score is 9, we modelled the Poisson
mean for the data (1.04) and calculated the probability that the value could be larger than 9
(1.58 × 10−7) to ensure that truncation of data relative to the Poisson distribution was not an
issue.
For Poisson regression with study as a random effect, age groups were included to stratify
the CHA2DS2-VASc mean estimates according to age brackets. The study-level covariates (i.e.,
geographical region, country, rural/urban population) were then added to the model one at a
time, and the Akaike information criterion was used to determine if they should be included
or not, based on comparison to the Akaike information criterion of the individual-level model.
The mean CHA2DS2-VASc scores were similar for each country, with one exception. The
mean score for this country was 1.7 (CI 1.2–2.4), while the next lowest was 2.4 (CI 1.6–3.5).
The inclusion of this country could unduly influence the overall summary estimates. To assess
the impact of these data in a sensitivity analysis, the model was refit without data from this
country, and the summary estimates were compared. The final model included data from all
countries.
Guideline recommendations for OAC were calculated for each new AF case with
CHA2DS2-VASc score and sex data. The ESC 2016 guidelines were used to classify OAC rec-
ommendations into (i) Class-1 OAC recommendation (CHA2DS2-VASc score: men� 2;
women� 3), (ii) consider OAC (CHA2DS2-VASc score: men = 1; women = 2), or (iii) OAC
not recommended (CHA2DS2-VASc score: men = 0; women = 1) [3]. Data are reported as
pooled number and percentages for each category and stratified according to age group (<60,
60–64, 65–69, 70–74, 75–79, 80–84,�85 years).
The number of additional stroke risk factors other than age and sex were calculated for
each person with new AF using the formula, CHA2DS2-VASc score − female sex point − age
points, and reported as a pooled percentage of all new AF, stratified according to age group.
NNS. The NNS to identify one new AF case was calculated using the inverse of the detec-
tion rate derived from the meta-regression, stratified according to age group. The NNS-Rx was
calculated using the inverse of the determined yield of newly identified AF with a 2016 ESC
Class-1 recommendation for OAC, stratified according to age group.
Results
The search strategy identified 41 screening studies, of which 17 did not meet the eligibility cri-
teria (Fig 1). Study authors from the 24 eligible studies were contacted via email, and 19 studies
[11–29] from 14 countries agreed to the collaboration and contributed screening data.
A combined total of 141,220 participants were screened (approximately 44% men; sample
size range, 1,000–59,505) (Table 1). Rates of detection of AF ranged from 0.35% in studies
recruiting�40 years to 2.34% in studies recruiting�65 years. Studies recruited from commu-
nity or population screening (n = 7), general practice (n = 6), outpatient clinics (n = 3), and
pharmacies (n = 3). The screening methods used were single-lead ECG (n = 12), 12-lead ECG
(n = 4), pulse palpation (n = 2), and modified blood pressure machine (n = 1).
New AF cases
From the pooled data (n = 19 studies), 1,539 new cases of AF were identified from 141,220 par-
ticipants screened. Limiting the results to people�65 years, 1,162 new cases of AF were identi-
fied from 74,104 participants screened. Absolute numbers of new AF identified were greatest
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within the range of 70–74 years (Fig 2). The pooled yield of screening was greater in males
across all age strata and increased in both men and women with increasing age (Fig 3).
AF detection rate
The inclusion of sex, age group, and cohort improved the fit of the random effects logistic
regression model. The variables of setting, method, region, country, urban/rural, era screened,
and screen age eligibility did not appear to influence the results. The final model was adjusted
for age group and sex, and incorporated 18/19 studies (n = 138,663) for which data on total
numbers screened were stratified by both age and sex [11–20,22–29]. The study-level random
effect estimate was 0.2320 (SE = 0.0889), indicating a heterogeneous sample.
The detection rate for cases of new AF identified through screening increased progressively
with increasing age, as presented in the summary estimates (Fig 4). Below age 60 years yield
Fig 1. Study selection.
https://doi.org/10.1371/journal.pmed.1002903.g001
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was 0.34%, increasing to 2.73% for ages 85 years and over. For screening people�65 years (as
per guideline recommendations), the detection rate of new AF was 1.44% (95% CI, 1.13%–
Table 1. Characteristics of studies.
Author, year Country,
study name
Setting Screening method Year
screened
Age
Eligibility
(years)
Number
screened
Proietti and
colleagues, 2016 [16]
Belgium,
Belgian Heart Rhythm
Week
Community/
population
Single-lead ECG (Omron HCG-801) 2010–
2014
�20 59,505
Schnabel and
colleagues, 2012 [11]
Germany,
Gutenberg Health
Study
Community/
population
12-lead ECG 2007–
2017
35–74 14,937
Yan and colleagues,
2017 [12]
Hong Kong Outpatient
clinic
Single-lead ECG (AliveCor) 2015–
2017
�40 12,928
Gomez-Doblas and
colleagues, 2014 [13]
Spain,
OFRECE
Community/
population
12-lead ECG 2010–
2012
�40 8,396
Deif and colleagues,
2013 [14]
Australia Outpatient
clinic
12-lead ECG 2011 �40 3,430
Soni and colleagues,
2017 [15]
India Community/
population
Single-lead ECG (AliveCor) 2016–
2017
�50 1,947
Li and colleagues,
2015 [17]
China Community/
population
12-lead ECG 2006–
2011
�60 3,922
Smyth and colleagues,
2016 [18]
Ireland General practice Pulse palpation (confirmed with 12-lead ECG) 2014 �60 7,262
Chao and colleagues,
2017 [19]
Taiwan,
SAFE-Taiwan
Pharmacy Modified blood pressure device (Microlife WatchBP Office
AFIB)
2015–
2016
�60 2,672
Kvist and colleagues,
2017 [20]
Denmark,
DANCAVAS
Community/
population
Single-lead ECG (Lead-II during Cardiac-CT scan) 2015–
2016
65–74 1,318
Kaasenbrood and
colleagues, 2016 [21]
the Netherlands General practice Single-lead ECG (MyDiagnostick) 2013 �65 2,557
Lowres and
colleagues, 2014 [22]
Australia,
SEARCH-AF
Pharmacy Single-lead ECG (AliveCor) 2012–
2013
�65 1,000
Sandhu and
colleagues, 2016 [23]
Canada,
PIAAF-Pharmacy
Pharmacy Single-lead ECG (HeartCheck, CardioComm) 2014–
2015
�65 1,145
Quinn and colleagues,
2018 [24]
Canada,
PIAAF-Family
Practice
General practice Single-lead ECG (HeartCheck, CardioComm); modified
blood pressure device (Microlife WatchBP Home A); and
pulse palpation (confirmed with 12-lead ECG ± holter)
2016–
2017
�65 2,054
Gonza´lez Blanco and
colleagues, 2017 [25]
Spain,
DOFA
General practice Pulse palpation (confirmed with 12-lead ECG) 2015–
2016
�65 7,063
Fitzmaurice and
colleagues, 2007 [26]
England,
SAFE (systematic
screening arm)
General practice 12-lead ECG 2001–
2003
�65 2,357
Orchard and
colleagues, 2018 [27]
Australia,
AF-SMART
General practice Single-lead ECG (AliveCor) 2016–
2017
�65 1,574
Keen and colleagues,
2017 [28]
United States Outpatient
clinic
Single-lead ECG (AliveCor) 2016–
2017
�65 2,732
Wang and colleagues,
2017 [29]
China Community/
population
Single-lead ECG (AliveCor) 2017–
2018
�65 4,421
Abbreviations: AF-SMART, atrial fibrillation screen management and guideline recommended therapy; DANCAVAS, Danish Cardiovascular Screening trial; DOFA,
Deteccio´n Oportunista de Fibrilacio´n Auricular en Atencio´n Primaria Study; ECG, electrocardiogram; OFRECE, Observacio´n de FibRilacion auricular y Enfermedad
Coronaria en España; PIAAF-Pharmacy, Program for the identification of ‘actionable’ atrial fibrillation in the pharmacy setting; PIAAF-Family Practice, Program for
the identification of ‘actionable’ atrial fibrillation in family practice; SAFE, screening for atrial fibrillation in the elderly; SAFE-Taiwan, screen of atrial fibrillation events
in Taiwan; SEARCH-AF, Screening education and recognition in community pharmacies of atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002903.t001
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1.82%), compared with only 0.41% (95% CI, 0.31%–0.53%) for people aged <65 years (rate
ratio = 3.57, 95% CI, 3.10–4.10) (Fig 5).
Stroke risk profile
CHA2DS2-VASc scores were available for 1,369 new AF cases, collected at the time of screen-
ing, from 18/19 studies [11–24,26–29]. As expected, mean CHA2DS2-VASc scores increased
progressively with age, with step increases at ages 65 and 75 years (Table 2). CHA2DS2-VASc
results appeared to be influenced by a country/cohort effect, with the highest CHA2DS2-VASc
Fig 2. Total numbers of new AF by sex. AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002903.g002
Fig 3. AF pooled yield by sex. AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002903.g003
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means (>3.0) observed in Germany, Hong Kong, and America and the lowest (<2.0) in India.
The results did not appear to be influenced by setting, method, urban/rural, era screened, or
screen age eligibility.
When considering only ‘non-age and non-sex’ factors of the CHA2DS2-VASc score, 72%
(712/993) of new AF�65 years had at least one additional stroke risk factor (comorbidity)
other than age or sex (Table 2). The number with comorbidities was lower in age groups 65–
69 and 70–74 years (65% and 69%, respectively); however, it was>75% in all three age strata
over 75 years.
Above age 65 years, the clear majority (84%) of screen-detected new AF was eligible for
OAC with a Class-1 recommendation, according to the 2016 ESC guidelines (Table 2) [3]. For
people aged�75 years, 100% had a Class-1 recommendation because of age alone. In the age
range 65–74 years, 66% received a Class-1 recommendation, and the remaining 34% had a rec-
ommendation to consider OAC (Table 2). In contrast, for those<65 years, only 26% received
Fig 4. AF detection rate (adjusted for age and sex). Summary estimates are calculated from the 18/19 studies that provided both gender and age for total numbers
screened. AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002903.g004
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a Class-1 recommendation, 23% had a recommendation to consider OAC, and half (51%) had
a recommendation to not prescribe OAC (Table 2).
NNS
When screening people�65 years, the NNS to identify one new AF is 69, rising to 83 to iden-
tify one treatable new AF (i.e., those with a Class-1 OAC recommendation). A progressive
increase was observed in both NNS to identify one new AF and NNS-Rx as the age group
decreased (Table 3). Specifically, there was a large jump noted between age 65–69 to 60–64
years, in which the NNS-Rx rose steeply from 211 to 926, and a further increase to 1,089 for
people aged <60 years (Table 3).
Discussion
To our knowledge, this is the first study to show the actual yield of screen-detected AF and
estimated stroke risk by age group, in very large numbers. Our data show that both yield and
Fig 5. AF detection rate for<65 years and 65+ years. Summary estimates are calculated from the 18/19 studies that provided both gender and age for total numbers
screened. AF, atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1002903.g005
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stroke risk are very sensitive to age, and the estimated stroke risk profile of new cases is high.
When screening�65 years, the detection rate of new AF cases is 1.44% (95% CI, 1.13%–
1.82%), and 84% of new AF cases have a Class-1 recommendation for OAC prophylaxis. Of
note, under the 2016 Canadian AF Guidelines, all people aged�65 years receive an OAC rec-
ommendation based on age alone [34]. The high stroke risk profile is not solely due to age and
sex, as 72% of new cases aged�65 years have at least one additional CHA2DS2-VASc stroke
risk factor (comorbidity) other than age or sex. As expected, with increasing age there is a cor-
responding continuous increase in the detection rate of new AF, mean CHA2DS2-VASc scores,
and additional CHA2DS2-VASc stroke risk factors. The yield of screening was higher in men
across all age groups, even though larger numbers of women were screened.
The detection rate of 1.44% for screening people�65 years is comparable to the result of
1.4%, determined from a systematic review of AF screening in 2013 [35]. Both of these results
are based on single time point screening and, as such, may be an underestimate of undetected
AF, as some cases of paroxysmal AF may be missed. Intermittent or continuous screening over
two weeks or longer will identify additional cases of paroxysmal AF, leading to a larger yield
[36–38]. Indeed, only one sixth of new AF cases were detected at baseline ECG testing in the
STROKESTOP trial, with the remainder detected during the subsequent two weeks of
Table 2. Stroke risk profile of new AF cases (n = 1,369).
Age group,
years
Number,
n
CHA2DS2-VASc,
mean� (95% CI)
�1 non-age/sex stroke risk factor,
percent of age group
Guideline Recommendation†
No OAC, percent Consider OAC, percent Prescribe OAC, Class-1 percent
<60 251 1.1 (0.7–1.5) 46 54 19 27
60–64 125 1.4 (1.2–1.6) 54 45.5 32 22.5
65–69 223 2.5 (2.2–2.8) 65 0 35 65
70–74 240 2.7 (2.4–2.9) 69 0 32.5 67.5
75–79 228 3.8 (3.4–4.1) 76 0 0 100
80–84 151 3.8 (3.4–4.2) 75 0 0 100
85+ 151 3.9 (3.6–4.4) 77 0 0 100
�Least square means.
†Recommendation according to the 2016 ESC AF guidelines.
Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc score, (congestive heart failure/left ventricular dysfunction, high blood pressure, age >75 years, diabetes, stroke/
transient ischaemic attack/thromboembolism, vascular disease [coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque], age 65–74 years,
sex category female); ESC, European Society of Cardiology; OAC, oral-anticoagulation.
https://doi.org/10.1371/journal.pmed.1002903.t002
Table 3. NNS.
Age group, years NNS to identify
1 new AF (n)
NNS to identify
1 treatable new AF (n)‡
<60 294 1,089
60–64 208 926
65–69 137 211
70–74 92 136
75–79 67 67
80–84 53 53
85+ 37 37
‡Newly identified AF with a Class-1 recommendation to prescribe OAC.
Abbreviations: AF, atrial fibrillation; NNS, number needed to screen; OAC, oral anticoagulation.
https://doi.org/10.1371/journal.pmed.1002903.t003
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intermittent screening [36]. The REHEARSE-AF study detected 3.8% with new AF by 1–2
ECGs per week over 1 year, although in that study, 1.8% of patients screened for eligibility by a
single ECG had new AF detected [39]. With two weeks of ambulatory ECG monitoring using
an adhesive patch in the mSToPS study, 5.1% were detected with new AF [38]. Although addi-
tional new AF cases are identified and the cost-effectiveness of intermittent screening has been
demonstrated in a targeted population of 75-year-olds, intensive screening is more expensive,
and stroke risk is lower for the most intensive screening programs (e.g., implanted cardiac
monitors) [40]. Therefore, intensive screening is not currently recommended for a generalised
population [41]. For this reason, this review focused solely on single time point screening, as it
corresponds with clinical practice and is well suited for opportunistic screening according to
guideline recommendations.
For implementation of opportunistic screening, our review indicates that the choice of
screening setting and the methodology/device chosen to screen (i.e., pulse palpation, single-
lead ECG, 12-lead ECG, or modified blood pressure machine) do not influence the detection
rate. Therefore, decisions on how to implement screening can be tailored to available local or
national resources, practice preference, the requirements of the health system, and the popula-
tion to be screened. Decisions around developing a screening program also critically require
consideration of the pathway to treatment, as 84% of new AF identified (aged�65 years) will
require a consultation for consideration of OAC prescription.
Our data do not support screening a general population younger than 65 years, as the yield
is low, and only 26% of new AF cases would receive a Class-1 recommendation to treat with
OAC. Even to consider screening people aged 60–64, the NNS-Rx increases markedly to 926,
compared with 211 for ages 65 to 69 years. For the population below 60 years, to identify one
treatable person requires screening 1,089 people. Screening people younger than 65 may be
appropriate in targeted populations (e.g., poststroke or in those with additional stroke risk fac-
tors), as both yield and stroke risk profile are likely to be higher, in which case the NNS-Rx
would reduce significantly [42,43].
The NNS data will be very important to determine precise estimates of cost-effectiveness.
To date, health-economic analyses from many countries, based on a similar yield of new AF,
have all demonstrated the likely cost-effectiveness of AF screening based on quality-adjusted
life years gained and strokes avoided [8,22,41,44–46]. Cost-effectiveness is sensitive to OAC
prescription rates and improves as OAC prescription rates increase [22]. Given the recent
trend of increased guideline-based prescription rates from 48% to 78.6% noted in the United
Kingdom since the introduction of non-vitamin K antagonist OACs [47], guideline-based
screening of people�65 years, assuming a yield of 1.44%, is likely to be more cost-effective
than some previously published estimates. However, cost-effectiveness calculations will also
need to consider the possible influence of increased bleeding risk and the associated costs,
including hospitalisations related to treatment with OAC for those with screen-detected AF
[48].
Furthermore, it is widely acknowledged there are no published outcome data (stroke and
death) for screen-detected AF [6,49]. In response to this, large screening studies with these
endpoints are currently underway (e.g., ClinicalTrials.gov Identifiers NCT02743416 [STRO-
KESTOP II] and NCT01593553). Once these and similar studies in the planning stages report,
the outcome data can be combined with data from this review to calculate the number needed
to treat to more precisely inform cost-effectiveness analyses and policy decisions on screening,
based on the age distribution of the specific population to be screened. It appears that screen-
ing for AF in a general population is likely to be cost-effective if screening is commenced at
age 65, in line with current international guidelines. However, actual cost-effectiveness will
depend on the age distribution of the population to be screened as well as stroke rates in each
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stratum of the new AF cases discovered. Our estimates of likely yield of both AF cases and pro-
portion of cases with an elevated calculated stroke risk enable organisations responsible for
healthcare delivery to determine the best age cutoffs to suit their own budgets. For example,
some organisations may decide on setting an age threshold of 70 or even 75 years, accepting a
trade-off in missed opportunities to prevent strokes.
Limitations
The heterogeneity between the included studies was high. We do not have sufficient data on
the sociodemographic variables of the populations screened, or possible ascertainment biases,
to explain the variance in the samples. As a logistic regression approach was chosen, we were
unable to assess funnel plot asymmetry; however, the rigorous methods for identification of
relevant studies will likely reduce the chance of publication bias. The detection rate of
unknown AF could also be inflated in a minority of studies, as self-knowledge/recall of past AF
history may be inaccurate, and studies performed in areas with reduced access to medical ser-
vices may have lesser rates of previous AF diagnoses. Furthermore, the data reported in this
review cannot take into account what proportion of new AF would have been detected, albeit
with some delay, without screening. Few of the included studies included a control population,
but in the large SAFE trial, the detection rate of new AF in practices screening people�65
years was 1.63% per annum, 1.04% per annum in control practices, and 1.0% in 1 year in the
control group of REHEARSE-AF [26,39].
Conclusions
People detected with new AF through screening are at elevated calculated stroke risk: above
age 65, the majority are eligible for and would benefit from OAC to prevent stroke, and>70%
have at least one additional stroke risk factor other than age or sex. Screening for AF in people
aged�65 years identifies new AF in 1.44% of those screened. The detection rate was not influ-
enced by the screening method, recruitment setting, country, or year screened. The detection
rate of new AF by screening rises progressively with age, with a male predominance in all age
strata. One treatable new AF will be identified for every 83 people screened in people aged�65
years. Our data show that the yield and stroke risk profile of new AF are sensitive to age, so the
NNS-Rx is dependent on the age distribution of the population to be screened; this informa-
tion is essential for precise calculations of cost-effectiveness of different age cutoffs for screen-
ing. Screening for AF in a general population is likely to be cost-effective if screening is
commenced at age 65, in line with current international guidelines. However, actual cost-effec-
tiveness will depend on the age distribution of the population to be screened, as well as stroke
rates in each age stratum of the new AF cases discovered.
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